Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels.

Li L, Yang G, Li Q, Tan X, Liu H, Tang Y, Boden G

Diabetes, obesity & metabolism17 Dec 2007Cited by 41 (Europe PMC)

PMID18093209DOI10.1111/j.1463-1326.2007.00832.xPepBankPUB-18093209

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In high fat-fed rats, exenatide prevented diet-induced body weight increases.
In plain wordsIn rats, exenatide prevented body weight increases compared with the high-fat diet control.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
ratn: not reported in source
high fat-fed rats
Comparator
High-fat diet control
Outcome group
Body weight · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Administration of exenatide (0.5 or 2.0 mug/kg twice daily x 6 weeks) prevented high-fat diet (HFD)-induced increases in body weight, plasma free fatty acids, triglycerides and total cholesterol.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320901
02AnimalAnimal study (in vivo)Efficacy outcome
In high fat-fed rats, exenatide prevented diet-induced plasma free fatty acid increases.
In plain wordsIn rats, exenatide prevented free fatty acid increases compared with the high-fat diet control.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma free fatty acids
Study
ratn: not reported in source
high fat-fed rats
Comparator
High-fat diet control
Outcome group
Lipids · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Administration of exenatide (0.5 or 2.0 mug/kg twice daily x 6 weeks) prevented high-fat diet (HFD)-induced increases in body weight, plasma free fatty acids, triglycerides and total cholesterol.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320902
03AnimalAnimal study (in vivo)Efficacy outcome
In high fat-fed rats, exenatide prevented diet-induced plasma triglyceride increases.
In plain wordsIn rats, exenatide prevented triglyceride increases compared with the high-fat diet control.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma triglycerides
Study
ratn: not reported in source
high fat-fed rats
Comparator
High-fat diet control
Outcome group
Lipids · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Administration of exenatide (0.5 or 2.0 mug/kg twice daily x 6 weeks) prevented high-fat diet (HFD)-induced increases in body weight, plasma free fatty acids, triglycerides and total cholesterol.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320903
04AnimalAnimal study (in vivo)Efficacy outcome
In high fat-fed rats, exenatide prevented diet-induced total cholesterol increases.
In plain wordsIn rats, exenatide prevented cholesterol increases compared with the high-fat diet control.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTotal cholesterol
Study
ratn: not reported in source
high fat-fed rats
Comparator
High-fat diet control
Outcome group
Lipids · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Administration of exenatide (0.5 or 2.0 mug/kg twice daily x 6 weeks) prevented high-fat diet (HFD)-induced increases in body weight, plasma free fatty acids, triglycerides and total cholesterol.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320904
05AnimalAnimal study (in vivo)Efficacy outcome
In high fat-fed rats, exenatide prevented deterioration in peripheral insulin sensitivity.
In plain wordsIn rats, exenatide preserved peripheral insulin sensitivity compared with the high-fat diet control.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePeripheral insulin sensitivity
Study
ratn: not reported in source
high fat-fed rats
Comparator
High-fat diet control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Exenatide also prevented HFD-induced deterioration in peripheral and hepatic insulin sensitivity, insulin clearance, glucose tolerance and decreased tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) in fat and skeletal muscles.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320905
06AnimalAnimal study (in vivo)Efficacy outcome
In high fat-fed rats, exenatide prevented deterioration in hepatic insulin sensitivity.
In plain wordsIn rats, exenatide preserved liver insulin sensitivity compared with the high-fat diet control.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHepatic insulin sensitivity
Study
ratn: not reported in source
high fat-fed rats
Comparator
High-fat diet control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Exenatide also prevented HFD-induced deterioration in peripheral and hepatic insulin sensitivity, insulin clearance, glucose tolerance and decreased tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) in fat and skeletal muscles.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320906
07AnimalAnimal study (in vivo)Efficacy outcome
In high fat-fed rats, exenatide prevented deterioration in insulin clearance.
In plain wordsIn rats, exenatide preserved insulin clearance compared with the high-fat diet control.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableInsulin clearance
Study
ratn: not reported in source
high fat-fed rats
Comparator
High-fat diet control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Exenatide also prevented HFD-induced deterioration in peripheral and hepatic insulin sensitivity, insulin clearance, glucose tolerance and decreased tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) in fat and skeletal muscles.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320907
08AnimalAnimal study (in vivo)Efficacy outcome
In high fat-fed rats, exenatide prevented deterioration in glucose tolerance.
In plain wordsIn rats, exenatide preserved glucose tolerance compared with the high-fat diet control.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGlucose tolerance
Study
ratn: not reported in source
high fat-fed rats
Comparator
High-fat diet control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Exenatide also prevented HFD-induced deterioration in peripheral and hepatic insulin sensitivity, insulin clearance, glucose tolerance and decreased tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) in fat and skeletal muscles.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320908
09AnimalAnimal study (in vivo)Mechanism
In high fat-fed rats, exenatide prevented decreased IRS-1 tyrosine phosphorylation in fat.
In plain wordsIn rats, exenatide preserved IRS-1 phosphorylation in fat compared with the high-fat diet control.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseIRS-1 tyrosine phosphorylation in fat
Study
ratn: not reported in source
high fat-fed rats
Comparator
High-fat diet control
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Exenatide also prevented HFD-induced deterioration in peripheral and hepatic insulin sensitivity, insulin clearance, glucose tolerance and decreased tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) in fat and skeletal muscles.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320909
10AnimalAnimal study (in vivo)Mechanism
In high fat-fed rats, exenatide prevented decreased IRS-1 tyrosine phosphorylation in skeletal muscle.
In plain wordsIn rats, exenatide preserved IRS-1 phosphorylation in muscle compared with the high-fat diet control.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseIRS-1 tyrosine phosphorylation in skeletal muscle
Study
ratn: not reported in source
high fat-fed rats
Comparator
High-fat diet control
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Exenatide also prevented HFD-induced deterioration in peripheral and hepatic insulin sensitivity, insulin clearance, glucose tolerance and decreased tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) in fat and skeletal muscles.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320910
11AnimalAnimal study (in vivo)Mechanism
In high fat-fed rats, exenatide decreased plasma visfatin levels.
In plain wordsIn rats, exenatide decreased plasma visfatin levels.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma visfatin
Study
ratn: not reported in source
high fat-fed rats
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Interestingly, plasma visfatin levels decreased in exenatide-treated rats, whereas expression and plasma levels of adiponectin increased.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320911
12AnimalAnimal study (in vivo)Mechanism
In high fat-fed rats, exenatide increased adiponectin expression.
In plain wordsIn rats, exenatide increased adiponectin expression.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdiponectin expression
Study
ratn: not reported in source
high fat-fed rats
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Interestingly, plasma visfatin levels decreased in exenatide-treated rats, whereas expression and plasma levels of adiponectin increased.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320912
13AnimalAnimal study (in vivo)Mechanism
In high fat-fed rats, exenatide increased plasma adiponectin levels.
In plain wordsIn rats, exenatide increased plasma adiponectin levels.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePlasma adiponectin
Study
ratn: not reported in source
high fat-fed rats
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
0.5 or 2.0 mug/kg twice daily · 6 weeksAs given in this study (rat).
Source sentences
Summary
Interestingly, plasma visfatin levels decreased in exenatide-treated rats, whereas expression and plasma levels of adiponectin increased.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we examined the effects of exenatide treatment on glucose tolerance (intravenous glucose tolerance test), insulin sensitivity (euglycaemic-hyperinsulinaemic clamps), insulin signalling (insulin receptor substrate 1 tyrosine phosphorylation) and adipocytokine levels (visfatin an…
Report a problemFND-1809320913

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels.

Summary

Results from this study13

Version history

Subjects

Publication types

MeSH terms